LONDON (Thomson Financial) - Acambis Plc. said Monday its trading
performance and financial position have continued to be in line with its
expectations since April 23.
On April 23, the vaccine developer announced it had been awarded a 10-year
contract to provide the U.S. Centers for Disease Control and and Prevention with
U.S.-based warm-base manufacturing of its ACAM2000* smallpox vaccine. It also
announced a placing and open offer to raise 40 million pounds.
Acambis said separately on Monday that it has received valid applications
from qualifying shareholders in respect of 27.5 million shares, representing
about 73 percent of 37.7 million new shares available under the placing and open
offer.
The company also said it has placed the remaining 10.2 shares with
shareholders seeking an additional allotment and with new investors at 115 pence
a share.
TFN.newsdesk@thomson.com
rda/kf1
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|